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Abstract
The Committee for Orphan Medicinal Products (COMP) evaluates prevalence of rare conditions as one of the
criteria for granting an orphan designation with a prevalence threshold of 5 in 10.000. At the time of Marketing
Authorisation (MA) these criteria are reassessed to ensure they are still met. The COMP has noted discordance
between the prevalence of certain haematological malignancies at the time of Orphan Designation and at the time
of Marketing Authorisation. Consequently, we conducted a retrospective assessment of Chronic Lymphocytic
Lymphoma and Multiple Myeloma/Plasma cell Myeloma as well as several other haematological rare aetiologies
frequently subject of orphan designation. These were: Diffuse large B-Cell Lymphoma (DLBCL), Follicular Lymphoma
(FL), Cutaneous T-Cell Lymphoma (CTCL), Mantle Cell Lymphoma (MCL) and Chronic Myeloid Leukaemia (CML). The
review used submissions as well as recent publications and results from external and EMA databases. As a first step
in the analysis, an increase over time in the number of people affected was evident for four conditions in the
COMP designation documents, whereas for DLBCL, FL, CTCL and MCL there had been no significant change, since
the introduction of the Regulation in 2000. Specifically, the prevalence estimates increased from 1.2 to 3.6 per
10,000 for multiple myeloma, from 0.4 to 1.7 in acute lymphoblastic leukaemia, and from 2.7 to 4.85 for chronic
lymphocytic leukaemia/small lymphocytic leukaemia and 1 to 2 in 10,000 for chronic myeloid leukaemia. The
reasons for the changes in the prevalence of these four haematological conditions over the last 15 years were not
assessed but recent publications have alluded to better outcomes due to new treatments being made available. In
addition, many orphan diseases have a median age of onset over 60 years so that also the aging of the population
may be a relevant contributing factor.
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Background
In 2000 the European Union introduced legislation to en-
courage the development of medicinal products for rare
diseases. This legislation established a scientific Commit-
tee including patients as full members, the Committee for
Orphan Medicinal Products (COMP) whose role is to as-
sess submissions for the designation of medicinal products
intended for the treatment, diagnosis or prevention of a
medical condition which is considered rare. The COMP
meets every month and discusses submissions for Orphan
Designation. The main criteria for assessment are the
eligibility of a proposed medical condition as a distinct
medical entity, the medical plausibility that the proposed
medicinal product holds therapeutic promise in the pro-
posed condition, that the prevalence of the condition is
less than or equal to 5 in 10,000 and where authorised
medicinal products exist in Europe, the medicinal product
will bring significant benefit for the patients affected by
the condition. The outcome of the positive assessments
(positive opinions) are made public each month following
each plenary, and can be found on a dedicated Orphan
Designation database available on the European Medicines
Agency and European Commission websites.
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The COMP receives many submissions for oncological
conditions, around 35% of all submissions each year. Rare
haematological malignancies (HMs) represent approxi-
mately 42% (228 OD in HMs/538 total ODs) of designa-
tions of orphan medicinal products in oncology granted
by the COMP from 2000 until May 2015 (Fig. 1).
Recently, members of the COMP have noted discord-
ance between prevalence calculations submitted for some
of these conditions and what is reported in the literature
in multiple myeloma and chronic lymphocytic leukaemia/
small lymphocytic lymphoma. This led to the sponsor’s
being requested during the procedure to re-calculate the
prevalence, or justify in an oral explanation the basis for
their calculation. As a result the EMA COMP and the Or-
phan Medicines Office conducted a retrospective analysis
of the most frequent haematologic conditions submitted
for Orphan Designation and compared the prevalence
reported by sponsors to those reported in recent publica-
tions for each of the conditions. The WHO 2008 Classifi-
cation system of haematological malignancies has been
used where possible by the COMP for haematological
conditions and was the basis of the conditions selected for
this analysis. The conditions chosen for the assessment
were: acute myeloid leukaemia (AML), acute lymphocytic
leukaemia, (ALL), cutaneous T-cell lymphoma (CTCL),
diffuse large B-cell lymphoma (DLBCL), follicular lymph-
oma (FL), Chronic myeloid leukaemia (CML), chronic
lymphocytic leukaemia/small lymphocytic lymphoma
(CLL/SLL), mantle-cell lymphoma (MCL), Multiple Mye-
loma (MM), Hodgkin’s Lymphoma (HL) and myelodys-
plastic syndrome (MDS).
The retrospective analysis showed that there was an in-
crease in the prevalence of four conditions namely mul-
tiple myeloma, acute lymphocytic leukaemia, chronic
lymphocytic leukaemia/small lymphocytic lymphoma and
chronic myeloid leukaemia. In the case of multiple mye-
loma and chronic lymphocytic leukaemia an increase was
noted at assessment by the COMP and not the submis-
sions from the sponsors. The reasons for the change in
the prevalence in these conditions were not the primary
aim of the analysis, however it was noted that peer
reviewed publications of the management and treatment
of patients affected by these conditions have reported bet-
ter outcomes potentially linked to the use of new medi-
cinal products introduced over that last 10 years.
Methodology
We looked at positive orphan designations in the EMA
database (at the time of initial Orphan Designation and
at the time of maintenance of the Orphan Designation)
for the following haematological conditions most com-
monly submitted to the COMP: acute myeloid leukae-
mia (AML), acute lymphoblastic leukaemia, (ALL),
cutaneous T-cell lymphoma (CTCL), diffuse large B-cell
lymphoma (DLBCL), follicular lymphoma (FL), Chronic
myeloid leukaemia (CML), chronic lymphocytic leukae-
mia/small lymphocytic lymphoma (CLL/SLL), mantle-
cell lymphoma (MCL), multiple myeloma (MM), Hodg-
kin’s lymphoma (HL) and myelodysplastic syndrome
(MDS). We examined retrospectively the prevalence esti-
mates across time (from 2000 to 2015) in these designa-
tions. The criteria applied to choose the conditions to be
analysed were the number of initial positive orphan des-
ignations granted and number of positive maintenance
of Orphan Designations (this step is conducted at the
time of Marketing Authorisation application, 3 to 4 years
after the designation on average for all designations), as
identified on the EMA website [2]. Submissions for MA
that were withdrawn following COMP negative opinion
were not included in the analysis. The COMP public
summary of opinion reports which appear on the EMA
website and the minutes of the COMP meetings have
been used to identify the prevalence estimates provided
by the sponsors, the type of prevalence proposed by the
sponsors (point prevalence or partial prevalence) and
any question related to the sponsor’s prevalence calcula-
tion raised by the Committee. Partial prevalence esti-
mates are reported over a limited period of time, such as
5-year or 10-year prevalence, capturing all living patients
who had been diagnosed cases in the timespan of the
preceding 5 or 10 years. Point prevalence is the
Fig. 1 Distribution of all orphan designations for haematological
malignancies in oncology 2000–2015 (Percentage details: AML 9,6%;
MM 6%; ALL 5%; CLL/SLL 5%; CDCL 3%; MDS 2%)
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proportion of a population that has the condition at a
specific point in time irrespective of the time of diagno-
sis. A literature search using Pubmed was conducted to
identify recent prevalence calculations for these condi-
tions and epidemiological databases (Haematological
Malignancy Research Network, Cancer research UK, Na-
tional Cancer Data Repository) were used to compare
with the outcomes of the COMP evaluation [3, 4, 8]. It
has been noted that there is little variance in reporting
rates between Member States for these conditions.
Limitations of the methods
This is a retrospective study based on the analysis of
data gathered from the scientific documents (applica-
tions) submitted over time. The prevalence estimates re-
ported result from the calculation exercise performed by
each applicant, whose methodology can vary individu-
ally, despite the European Medicines Agency guidance
document, “Point to consider on the calculation and
reporting of the prevalence of a condition for orphan
designation”; this document has however not been up-
dated since 2002. Furthermore, the prevalence values
have not been standardised, meaning that they have been
pulled together irrespective of epidemiological index
used. Therefore, variability of data due to methodo-
logical factors needs to be taken into account in the in-
terpretation of the findings. In many ways this is main
driver of the variance. Factors such as the use or not of
European Member State cancer registries as well as the
selection of publications based on older or current arti-
cles can drive variance has been noted at the time of
assessment.
Another point worth to clarifying is related to the type
of prevalence reported. In earlier designations for mul-
tiple myeloma and chronic lymphocytic leukaemia/
small lymphocytic lymphoma, partial prevalence was ac-
cepted as life expectancy was considered to be limited.
As the literature reported improvements in survival and
in view of the aging population, COMP members have
recently requested point prevalence as it also helps to
bring into consideration the increase in the reported
prevalence for the two conditions of multiple myeloma
and chronic lymphocytic leukaemia/ small lymphocytic
lymphoma. This was not the case for ALL. For the other
conditions studied, the COMP did not find any increase
in the literature of either point or partial prevalence. It
should however be noted that there was an increase in
prevalence in CML with the introduction of Glivec [9].
Results
Figure 2 indicates the prevalence reported for the haem-
atological conditions analysed.
As can be seen reporting rates have been stable for
DLBCL, FL, HL, MCL and AML and the published lit-
erature does not report changes. There has been an in-
crease in CML from 1 in 10,000 reported in 2001, to 2
in 10,000 in 2012. A more significant rise in CLL/SLL
and MM can be seen in this report from 2013 for MM
and 2014 for CLL/SLL. In the case of ALL, there has
been a slow increase from 0.4 in 10,000 in 2001 to 1.35
in 10,000 in 2015. This is presented in the Fig. 3.
For conditions of very low prevalence, chronic myeloid
leukaemia and acute lymphoblastic leukaemia the COMP is
not requesting changes in how the prevalence calculations
Fig. 2 Prevalence reported for OD trends submitted to the COMP for Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Chronic
Myeloid Leukaemia (CML), Hodgkin’s Lymphoma (HL), Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukaemia/ Small Lymphocytic Lymph-
oma CLL/SLL, Multiple Myeloma (MM) and Acute Myeloid Leukaemia (AML) and Acute Lymphoblastic Leukaemia (ALL) between 2000 and 2015
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are made for orphan submissions. It has only been in con-
ditions where there have been public reports of higher
prevalence that the COMP has become more demanding
regarding the prevalence calculations submitted.
In the conditions where there was an increase in the
prevalence since the introduction of the orphan legislation,
7 medicinal products have been authorised, for multiple
myeloma (Carfilzomib, Daratumumab, Dexamethasone,
Lenalidomide, Panobinostat, Pomalidomide, and Thalido-
mide), 3 for chronic lymphocytic leukaemia/ small lympho-
cytic lymphoma (Obinutuzumab and Ofatumumab,
ibrutinib), 6 for acute lymphoblastic leukaemia (Clofara-
bine, Dasatinib, Imatinib, Mercaptopurine, Nelarabine,
Ponatinib) and 5 for chronic myeloid leukaemia (Bosutinib,
Dasatinib, Imatinib, Nilotinib, and Ponatinib).
One medicinal product each was authorised under the
orphan legislation for follicular lymphoma (Gazyvaro),
two for mantle cell lymphoma (Temsirolimus, Ibrutinib),
one for hodgkin’s lymphoma (Brentuximab Vedotin),
and four for acute myeloid leukaemia (Ceplene, Azaci-
dine, Decitabine and Histamine dihydrochloride). There
have been none authorised for diffuse large B-cell
lymphoma. It should also be noted that some products
have received authorisation for these conditions without
Orphan Designation such as idelalisib.
From the data available to the EMA, it is not possible
to conclude as to whether the introduction of these
medicines has improved patient outcomes.
Discussion
The COMP is mandated to give access to incentives for
the development of medicinal products and thereby
make medicinal products available for patients affected
by rare diseases. According to the regulation 141/2000,
the threshold of prevalence of a proposed orphan condi-
tion has to be met “at the time of application”. Since the
designation is reviewed at MA, updated prevalence fig-
ures may be necessary at review. In reviewing medicines
intended for rare diseases, the Committee noted discrep-
ancies in the reporting of current prevalences by spon-
sors in their submissions for certain haematological
conditions in Orphan Designation submissions both at
the time of initial designation and at the time of market-
ing authorisation review (so-called maintenance of Or-
phan Designation) compared with recent published
reviews. Prevalence changes can be expected in case of
rising incidence or improved survival of patients with
the condition. Expected changes in the demography of
the European the population (aging of the babyboomer
generation) are expected to result in substantial increase
of the prevalence of conditions diseases with a median
onset of over 60 years.
There has been some speculation within the COMP
and in the published literature regarding the number of
new products introduced in the market since it started
designating medicinal products and their impact on im-
provement in patient outcome. Whether outcome and
Fig. 3 Prevalence trends as reported above submitted to the COMP for a) multiple myeloma, b) chronic lymphocytic leukaemia/small
lymphocytic lymphoma and c) acute lymphoblastic leukaemia during the timeframe 2000–2015
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survival improvements are the main factors responsible
for increased prevalence is open up for interpretation, as
most of the conditions have had at least one product
authorised for use in the target condition, except diffuse
large B-cell Lymphoma.
We now present an example for each of the conditions
where increased prevalence has been observed.
Multiple myeloma
The minutes of the assessment of EMA/COMP Procedure
EMA/OD/277/14 for multiple myeloma highlight the first
case where the COMP questioned the prevalence calcula-
tion submitted by a sponsor for this condition [5]. The
sponsor was asked to re-evaluate the prevalence based on
more recent epidemiological publications and consult-
ation of databases, which have shown improved survival
and prognosis. The sponsor’s answer acknowledged the
recently reported improved prognosis and patient survival
for the condition compared to older publications (6.1 years
survival reported in 2015 versus 4.5 years in older publica-
tions). Results from literature search show an improved
survival for multiple myeloma has been recently reported
in the literature [6]. Epidemiological analysis published by
Kumar and Sant groups (2015) provides evidence in sup-
port of continued improvement in the survival outcomes
within the past decade.
Interestingly, significant survival improvement has
been seen among the older patients, whereas previously
described improvements were mainly in the younger pa-
tients, possibly as a reflection of lower utilisation of stem
cell transplantation and reduced access to clinical trials
evaluating new drugs [1, 7].
Databases such as Cancer research UK indicate similar
results to recent publications with improved current sur-
vival rates across several European countries: the 5-year
survival rates range from 23.1% to 46.7% [10, 11]. This
database includes myeloma survival rates in the UK
since the early 1970s [8]: over this period, five-year age-
standardised net survival for adults increased from
11.9% in the ‘70s to 47% in 2010–2011. The 10-year sur-
vival rate increased from 6.4% to 32.5% in the same
timeframe. These findings put into question the useful-
ness of the 5-year point prevalence for the purpose of
orphan designation, and the COMP now requires that
point prevalence be used for this condition.
Chronic Lymphocytic leukaemia/ small lymphocytic
lymphoma
The minutes of the assessment of EMA/COMP Proced-
ure EMA/OD/108/15 [5] show that the sponsor was
asked to re-assess prevalence based on possible increas-
ing survival rates reported in the literature [1]. The
sponsor’s response acknowledged the increase and
amended the prevalence estimate to 4.9 per 10.000. The
findings in the literature are also supported by data in
the Cancer Research UK and the National Cancer Data
Repository- NCDR) [8].
Conclusion
The COMP recently noted a discrepancy in prevalence
calculations and what has been reported in publications
for some haematological conditions, which qualify as
rare conditions under the European Orphan legislation.
Sponsors are reminded that previously accepted preva-
lence calculations which are publicly accessible on the
EMA website, are indicative of the prevalence at the mo-
ment that the designation was made. At the time of
Maintenance of Orphan Status at the time of Marketing
Authorisation, the sponsors should check current re-
ported prevalences as they can change over time due to
a multitude of factors such as the introduction of new
medicinal products and an improved understanding of
the condition. The COMP actively and critically assesses
the prevalence submissions and considers up to date epi-
demiological literature and database reports in a given
condition. Prevalence calculations, especially for ex-
tremely rare diseases are typically associated with a high
degree of uncertainty. Therefore, justifications of selec-
tion of sources or sensitivity analyses are recommended.
Criteria for prevalence calculations, such as the accept-
ability of partial prevalence versus point prevalence, can
change in case of reported improvements in patient out-
comes and additionally may depend on characteristics of
the disease. Therefore, sponsors are asked to specify and
justify the epidemiological index on which they base
their final conclusion of prevalence.
The impact of the new medicinal products authorised
under the European Orphan Legislation as well as those
not authorised under this incentive programme, on pa-
tient outcomes and survival was not the primary aim of
this retrospective analysis and would require further data
and assessment. It was primarily the rising concern in the
COMP of the discrepancy seen between reported submit-
ted prevalence’s for some of these conditions and what is
being currently reported in the public domain which was
a primary motive for this retrospective analysis.
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